mifepristone has been researched along with Substance Withdrawal Syndrome in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joshi, S; Kapur, J; Shiono, S; Williamson, J | 1 |
| Berry, JN; Butler, TR; Prendergast, MA; Reynolds, AR; Sharrett-Field, L | 1 |
| Forster, GL; Hassell, JE; Li, H; Renner, KJ; Scholl, JL; Tu, W; Watt, MJ | 1 |
| Laorden, ML; Milanés, MV; Navarro-Zaragoza, J | 1 |
| Coulton, S; Donoghue, K; Drummond, C; Little, H; Milward, J; Reed, K; Rose, A | 1 |
| Croft, AP; Jacquot, C; Little, HJ; Mulholland, P; Prendergast, MA; Shaw, SG | 1 |
| Cao, J; Dong, Z; Han, H; Xu, L | 1 |
| Hidalgo, JM; Laorden, ML; Milanés, MV; Navarro-Zaragoza, J | 1 |
| Barbier, E; Heilig, M; Koob, GF; Logrip, ML; Misra, KK; Repunte-Canonigo, V; Rivier, C; Sanna, PP; Schlosburg, JE; Vendruscolo, LF; Whitfield, TW; Zorrilla, EP | 1 |
| Avila, AH; Bayer, BM; Morgan, CA | 1 |
| Harris, BR; Little, HJ; Littleton, JM; Mulholland, PJ; Prendergast, MA; Self, RL | 1 |
| Cao, J; Dong, Z; Han, H; Mao, R; Xu, L | 1 |
| Cao, J; Dong, Z; Han, H; Luo, J; Tian, M; Xu, L; Xu, T; Zhong, W | 1 |
| Hajhashemi, V; Mesripour, A; Rabbani, M | 1 |
| Capasso, A; Di Giannuario, A; Loizzo, A; Pieretti, S; Sagratella, S; Sorrentino, L | 1 |
1 trial(s) available for mifepristone and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Cognition Disorders; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Mifepristone; Substance Withdrawal Syndrome | 2016 |
14 other study(ies) available for mifepristone and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Progesterone receptor activation regulates seizure susceptibility.
Topics: Animals; Female; Mifepristone; Norprogesterones; Pilocarpine; Progesterone; Rats; Rats, Sprague-Dawley; Receptors, Progesterone; Seizures; Status Epilepticus; Substance Withdrawal Syndrome | 2019 |
Mifepristone pretreatment reduces ethanol withdrawal severity in vivo.
Topics: Alcoholism; Animals; Body Weight; Corticosterone; Drug Evaluation, Preclinical; Eating; Ethanol; Hormone Antagonists; Male; Mifepristone; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Severity of Illness Index; Substance Withdrawal Syndrome | 2013 |
Serotonergic responses to stress are enhanced in the central amygdala and inhibited in the ventral hippocampus during amphetamine withdrawal.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Central Amygdaloid Nucleus; Central Nervous System Agents; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Hippocampus; Male; Microdialysis; Mifepristone; Motor Activity; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Restraint, Physical; Serotonin; Stress, Psychological; Substance Withdrawal Syndrome | 2014 |
Glucocorticoid receptor but not mineralocorticoid receptor mediates the activation of ERK pathway and CREB during morphine withdrawal.
Topics: Analgesics, Opioid; Animals; Cyclic AMP Response Element-Binding Protein; Dopamine; Hormone Antagonists; Male; MAP Kinase Signaling System; Mifepristone; Mineralocorticoid Receptor Antagonists; Morphine; Naloxone; Narcotic Antagonists; Nucleus Accumbens; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2017 |
Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption.
Topics: Alcohol Drinking; Animals; Glucocorticoids; Hormone Antagonists; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mifepristone; Substance Withdrawal Syndrome | 2008 |
Opioid withdrawal for 4 days prevents synaptic depression induced by low dose of morphine or naloxone in rat hippocampal CA1 area in vivo.
Topics: Analgesics, Opioid; Animals; CA1 Region, Hippocampal; Excitatory Postsynaptic Potentials; Male; Mifepristone; Morphine; Naloxone; Narcotic Antagonists; Neuronal Plasticity; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, N-Methyl-D-Aspartate; Stress, Psychological; Substance Withdrawal Syndrome; Synapses; Synaptic Transmission; Time Factors | 2010 |
Glucocorticoid receptors participate in the opiate withdrawal-induced stimulation of rats NTS noradrenergic activity and in the somatic signs of morphine withdrawal.
Topics: Animals; Hormone Antagonists; Male; Mifepristone; Morphine Dependence; Naloxone; Narcotic Antagonists; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Solitary Nucleus; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2012 |
Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Behavior, Addictive; Brain; Central Nervous System Depressants; Compulsive Behavior; Conditioning, Operant; Ethanol; Hormone Antagonists; Male; Mifepristone; Rats; Rats, Wistar; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Reinforcement Schedule; RNA, Messenger; Self Administration; Substance Withdrawal Syndrome; Up-Regulation | 2012 |
Stress-induced suppression of the immune system after withdrawal from chronic cocaine.
Topics: Adrenalectomy; Animals; Cell Division; Cocaine; Corticosterone; Disease Models, Animal; Dopamine Uptake Inhibitors; Hormone Antagonists; Hypersensitivity, Delayed; Immune System; Leukocytes; Male; Mifepristone; Rats; Stress, Physiological; Substance Withdrawal Syndrome; T-Lymphocyte Subsets; T-Lymphocytes | 2003 |
Corticosterone increases damage and cytosolic calcium accumulation associated with ethanol withdrawal in rat hippocampal slice cultures.
Topics: Animals; Calcium; Central Nervous System Depressants; Corticosterone; Cytosol; Ethanol; Female; Fluorescent Dyes; Hippocampus; Hormone Antagonists; Male; Mifepristone; Mineralocorticoid Receptor Antagonists; Organ Culture Techniques; Organic Chemicals; Propidium; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, N-Methyl-D-Aspartate; Spironolactone; Substance Withdrawal Syndrome | 2005 |
Morphine withdrawal modifies antinociceptive effects of acute morphine in rats.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Drug Tolerance; Male; Mifepristone; Morphine; Morphine Dependence; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Glucocorticoid; Stress, Psychological; Substance Withdrawal Syndrome | 2006 |
Stress evoked by opiate withdrawal facilitates hippocampal LTP in vivo.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Analysis of Variance; Animals; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Hippocampus; Hormone Antagonists; In Vitro Techniques; Long-Term Potentiation; Male; Mifepristone; Morpholines; Patch-Clamp Techniques; Phenols; Piperidines; Rats; Rats, Sprague-Dawley; Stress, Psychological; Substance Withdrawal Syndrome; Time Factors | 2006 |
Metyrapone and mifepristone reverse recognition memory loss induced by spontaneous morphine withdrawal in mice.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Glucocorticoids; Hormone Antagonists; Injections, Subcutaneous; Male; Memory; Memory Disorders; Metyrapone; Mice; Mifepristone; Morphine; Receptors, Glucocorticoid; Recognition, Psychology; Steroid 11-beta-Hydroxylase; Substance Withdrawal Syndrome; Time Factors | 2008 |
Dexamethasone selective inhibition of acute opioid physical dependence in isolated tissues.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Cycloheximide; Dexamethasone; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Guinea Pigs; In Vitro Techniques; Male; Mifepristone; Muscle Contraction; Naloxone; Opioid-Related Disorders; Pyrrolidines; Rabbits; Substance Withdrawal Syndrome | 1996 |